FLAGSTAFF, Ariz.--(BUSINESS WIRE)--W. L. Gore & Associates (Gore) today announced that it has received approval from the US Food & Drug Administration (FDA) to market its GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface for vascular bypass in the Superficial Femoral Artery (SFA). The GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface combines Gore’s proprietary heparin surface treatment with the proven performance of the GORE VIABAHN® Endoprosthesis for treatment of Peripheral Vascular Disease (PVD) in the SFA. In the US alone, as many as 12 million people suffer from some form of PVD.
